Drugs anticipated to be selected for Medicare price negotiation in 2026 for implementation in 2028

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Policy changes may limit negotiations on high-cost drugs in Medicare, suggesting potential higher spending ahead.

Drugs anticipated for negotiation in 2028 may not include high-cost products due to policy exclusions.
The implications of the OBBBA suggest a focus on high-spend drugs for savings in the Medicare program.
Negotiation for Part B drugs marks a first under new policies, affecting future drug pricing strategies.
Meaningful savings for Medicare could be hindered by the exclusion of specific high-cost drugs from negotiation.

Cousin et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark